Poor
Misaligned
Patient Risk:
Low
Summary
The response primarily discusses costs, patents, and alternative drugs, none of which are supported by the provided FDA label excerpts. The only on-label content (premature discontinuation/neuraxial hematoma/periprocedural discontinuation timing) is not actually represented in the listed statements, so label-alignment for the drug-label content provided is poor.
Category Scores
Accurate Statements
Key patents for dabigatran etexilate have already expired or are set to expire in the near future, with earliest expiry dates noted around 2025.
Unsupported by the provided FDA label excerpts.
Multiple patents can cover a single drug.
Unsupported by the provided FDA label excerpts.
Unsupported Statements
The cost of Pradaxa (dabigatran etexilate mesylate) can vary significantly depending on insurance coverage, pharmacy, and dosage.
No cost/coverage/payer statements are present in the supplied FDA label excerpts.
Without insurance, a 30-day supply of Pradaxa can cost several hundred dollars.
No pricing information is present in the supplied FDA label excerpts.
One source indicates a price of approximately $750 for a 30-day supply of 150 mg capsules.
No pricing information is present in the supplied FDA label excerpts.
Higher strengths or larger quantities of Pradaxa will naturally cost more.
No pricing relationship guidance is present in the supplied FDA label excerpts.
Different pharmacies may have different pricing structures for Pradaxa.
No pharmacy pricing information is present in the supplied FDA label excerpts.
Prescription drug plans can reduce out-of-pocket costs for Pradaxa through copays or coinsurance.
No payer/copay/coinsurance information is present in the supplied FDA label excerpts.
Some insurance plans may require prior authorization or have preferred drug lists for Pradaxa.
No prior authorization/formulary information is present in the supplied FDA label excerpts.
The manufacturer of Pradaxa, Boehringer Ingelheim, offers a patient assistance program for eligible uninsured or underinsured patients that can provide the medication at little to no cost.
No patient assistance program information is present in the supplied FDA label excerpts.
Key patents for dabigatran etexilate have already expired or are set to expire in the near future, with earliest expiry dates noted around 2025.
No patent/market exclusivity information is present in the supplied FDA label excerpts.
Multiple patents can cover a single drug.
No patent information is present in the supplied FDA label excerpts.
Secondary patents or exclusivities can extend market protection for a drug.
No exclusivity/patent-duration information is present in the supplied FDA label excerpts.
Other anticoagulant medications that may serve as alternatives to Pradaxa include other direct oral anticoagulants (DOACs) such as apixaban (Eliquis), rivaroxaban (Xarelto), and edoxaban (Savaysa), as well as warfarin.
The supplied FDA label excerpts do not list alternatives or comparative therapy.
Generic versions of some of these alternative anticoagulants are available and can significantly reduce the price.
No generic availability or pricing statements are present in the supplied FDA label excerpts.
Contradictions
Low
AI Statement
None of the listed statements directly conflict with the supplied FDA label excerpts.
Label Reference
N/A
Important Omissions
Boxed-warning and warnings content actually relevant to safety (premature discontinuation thrombotic risk; spinal/epidural hematoma risk; neuraxial timing considerations; monitoring for neurological impairment) is not addressed in the listed statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are about costs, patents, and alternatives; they do not directly provide incorrect dosing or safety instructions from the supplied FDA label excerpts. However, omission of on-label safety warnings (neuraxial hematoma and premature discontinuation guidance) limits label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Most statements are unsupported by the provided FDA label excerpts because they concern pricing, payer programs, patents, and alternative therapies not covered in the excerpts.
Suggested Improvement
If evaluating label alignment, restrict claims to label-supported content (e.g., boxed warning on premature discontinuation and neuraxial/spinal hematoma, and periprocedural discontinuation timing per Section 2.8), or provide appropriate non-label sources for pricing/patent/assistance claims.